Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Long-Term Deferred Tax (2022)

Historic Long-Term Deferred Tax for Spyre Therapeutics (SYRE) over the last 1 years, with Q4 2022 value amounting to $566000.0.

  • Spyre Therapeutics' Long-Term Deferred Tax changed N/A to $566000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $566000.0, marking a year-over-year change of. This contributed to the annual value of $566000.0 for FY2022, which is N/A changed from last year.
  • Per Spyre Therapeutics' latest filing, its Long-Term Deferred Tax stood at $566000.0 for Q4 2022.
  • Spyre Therapeutics' Long-Term Deferred Tax's 5-year high stood at $566000.0 during Q4 2022, with a 5-year trough of $566000.0 in Q4 2022.